News | July 21, 2021
Syngene Q1 FY22 revenue grows 41%
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
SteriScience will infuse an additional amount of Rs. 74.5 crore, making a total investment commitment of Rs. 114.5 crore in BSL
The company has already embarked upon significant expansion in Turkey
The distribution agreement is effective from 1 October 2021 and applies to Bormed products used in pharmaceutical packaging, medical and diagnostic devices
The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
The first batch will be shipped to the Gamaleya Center for the quality control
The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli in India
Subscribe To Our Newsletter & Stay Updated
